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Legionella SBT applied directly 
to respiratory samples as a rapid 
molecular epidemiological tool
Sara Quero1, Noemí Párraga-Niño1, Miquel Sabria1,2,3, Irene Barrabeig4, Maria Rosa Sala4, 
Mireia Jané4, Lourdes Mateu1,2,3, Nieves Sopena1,2,3, Maria Luisa Pedro-Botet1,2,3 & 
Marian Garcia-Nuñez1,2,5
Legionnaires’ disease (LD) is an atypical pneumonia caused by the inhalation of Legionella. The 
methods used for the diagnosis of LD are direct culture of respiratory samples and urinary antigen 
detection. However, the sensitivity of culture is low, and the urinary antigen test is specific only for L. 
pneumophila sg1. Moreover, as no isolates are obtained, epidemiological studies cannot be performed. 
The implementation of Nested-sequence-based typing (Nested-SBT) makes it possible to carry out 
epidemiological studies while also confirming LD, especially in cases caused by non-sg 1. Sixty-two 
respiratory samples from patients with Legionella clinically confirmed by positive urinary antigen 
tests were cultured and tested by Nested-SBT, following the European Study Group for Legionella 
Infections (ESGLI) protocol. Only 2/62 (3.2%) respiratory samples were culture-positive. Amplification 
and sequencing of Nested-SBT genes were successfully performed in 57/62 samples (91.9%). The seven 
target genes were characterised in 39/57 (68.4%) respiratory samples, and the complete sequence 
type (ST) was obtained. The mip gene was the most frequently amplified and sequenced. Nested-
SBT is a useful method for epidemiological studies in culture-negative samples, achieving a 28.7-fold 
improvement over the results of culture studies and reducing the time needed to obtain molecular 
epidemiological results.
Legionnaires’ Disease (LD) is an atypical pneumonia caused by the inhalation of aerosols containing Legionella 
and is considered to be responsible for between 2% and 13% of cases of community-acquired pneumonia requir-
ing hospitalisation1,2. The clinical manifestations of LD are not specific, and laboratory tests are crucial to confirm 
the diagnosis of the disease. The methods currently used for LD diagnosis are direct culture of respiratory sam-
ples, urinary antigen detection, serology, and direct fluorescent-antibody detection3. Approximately half of the 59 
species of Legionellae have been associated with human disease; however, Legionella pneumophila is responsible 
for more than 90% of cases of LD, with serogroup 1 (of the 16 serogroups identified to date) accounting for almost 
85% of cases4–6. This disproportionately high number of cases of L. pneumophila sg 1 is generated, in part, by the 
widespread use of urine antigen detection for LD diagnosis, a method that is specific for L. pneumophila sg 1.
The reporting of LD is mandatory in Spain and in other countries. Hence, when a case or outbreak of LD is 
declared, epidemiological studies must be carried out to find the source in order to be able to disinfect it and thus 
prevent further cases. Furthermore, under Spanish law, there may be major legal consequences for companies on 
whose premises an outbreak has occurred. Thus, the priority actions to be undertaken in outbreaks of Legionella 
include establishing the exact source of LD as well as ending the outbreak and determining risk factors in order 
to prevent future outbreaks. The molecular epidemiological tools currently used in Legionella laboratories are 
pulsed-field gel electrophoresis (PFGE) and sequence-based typing (SBT)3,7,8, and recently, Whole Genome 
Sequencing (WGS) has become increasingly popular9–11. These methods have great discriminatory power8, but 
they were designed to be applied after obtaining the isolates from samples. The main drawback of molecular 
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epidemiology studies of Legionella resides in the low efficiency of recovery from microbiological cultures, even 
when the protocol is performed by experienced laboratory staff12,13.
The European Working Group for Legionella Infections (EWGLI), now renamed the European Study Group 
for Legionella Infections (ESGLI), has recently improved and optimised the Nested-SBT protocol14 originally 
developed by Ginevra et al.15. Nested-SBT is a modification of the SBT method, which can be directly applied to 
respiratory samples. Several studies have evaluated this method’s efficacy in respiratory samples from which the 
isolate has previously been obtained in order to corroborate the concordance of the results15,16.
The aim of this study was to evaluate the utility of Nested-SBT as a rapid molecular epidemiological tool. For 
this evaluation, a total of 62 respiratory samples previously diagnosed with LD by urinary antigen testing were 
studied using microbiological culture and Nested-SBT.
Results
Microbiological culture and SBT. Only two out of 62 (3.2%) respiratory samples were culture-positive. 
The isolates were characterised as L. pneumophila sg 1 Knoxville ST20 and Knoxville ST146 (Table 1).
Nested-SBT. Amplification and sequencing of Nested-SBT genes were successfully performed in 57 out of 
62 respiratory samples (91.9%). In 39 samples (68.4%) the seven target genes were characterised and a complete 
sequence type (ST) was obtained. In 11 samples six genes were characterised, in four samples five genes, in one 
sample four genes and in two only two genes. In five (8.1%) samples positive by the urine antigen test, none of the 
seven target genes were amplified (Table 1).
The 39 samples with SBT profiles belonged to 25 different STs (index of diversity [IOD]: 0.972; 95% CI: 0.952–
0.991). Eleven STs were new SBT combinations, and 14 were already in the EWGLI database. The most frequent 
STs were ST92 and ST146, found in four respiratory samples each, followed by ST62 and ST17, found in three 
respiratory samples each. These four STs represented 28% of the complete STs.
The mip gene fragment was the most frequently amplified and sequenced (56 specimens).
Although the ability to obtain typing results did not show concordance (11.3%: kappa index = 0.006, 95% CI: 
−0.02–0.037) between culture-SBT and direct Nested-SBT, the ST identified in the direct sputum samples was the 
same as the ST in the L. pneumophila recovered from the two corresponding culture-positive samples.
Discussion
Due to the lack of characteristic symptoms of the disease, diagnosis of LD may be difficult. It is therefore vital 
to have access to accurate diagnostic methods in order to confirm clinical suspicion. The most commonly used 
method today for the diagnosis of LD is urinary antigen detection together with respiratory sample culture, which 
is the gold standard3. The main drawbacks of urinary antigen detection are that the strains are not isolated to per-
form molecular epidemiological studies, and that the test is specific only for L. pneumophila sg 1 and some cases 
of L. pneumophila sg 2–15. Indeed, using urinary antigen detection most cases are associated with L. pneumophila 
sg 1; around 40% of cases of LD are missed, especially those that are hospital-acquired6.
When a case of LD is confirmed, epidemiological studies are carried out in order to identify the source of 
infection and to initiate disinfection measures so as to avoid the appearance of new cases triggered by the colo-
nised facility. Molecular epidemiological studies are performed by comparing the molecular pattern of the clinical 
isolates with that of the environmental isolates found in the facilities under suspicion. However, the percentage of 
recovery of direct respiratory sample cultures is very low12.
In the present study, we assessed the utility of the Nested-SBT method as a rapid molecular epidemiological 
tool. Culture and Nested-SBT were performed in 62 respiratory samples collected from patients previously diag-
nosed by urinary antigen detection. While the culture of the samples was positive in only two cases, we obtained 
the complete SBT profile in 39 samples. The two respiratory samples in which the isolates were obtained showed 
the same ST in both the isolates and the respiratory samples, as reported previously15–17. Furthermore, although 
the SBT profile was not complete, in 18 samples at least two genes were amplified and sequenced.
The previous studies performed using Nested-SBT were based on the determination of the correlation of 
the results from the SBT of the isolates recovered and from the Nested-SBT of the respiratory samples15,16. We 
assessed the capacity of Nested-SBT to obtain molecular-epidemiological data in culture-negative samples. In 
culture-SBT, complete sequencing data were obtained in only 3.2% of samples, but in Nested-SBT the figure 
rose to 91.9% (57/62) – a 28.7-fold increase. These results were similar to those reported by Ginevra et al.15 and 
improve the results from studies which applied different semi-nested protocols12.
These differences show the great potential of Nested-SBT as a molecular epidemiological tool applied directly 
in respiratory samples. Although we obtained positive Nested-SBT results in 57 samples, only 68.4% of these 
were completely typed, obtaining the amplification and sequence of the seven target genes. In the remaining 
samples only partial amplification and sequencing was achieved; allowing facilities considered as suspicious to be 
ruled out but not confirming the facility causing the cases or outbreak. Furthermore, the method allowed us to 
corroborate or rule out the hypothesis of the possible relationship between samples (Table 1). While Nested-SBT 
confirmed the molecular relationship of cases 26 and 27 and 43 and 44, it ruled out a molecular relationship in 
cases 4 and 5, 8 and 9, and between 40 and 41 and 42.
The use of Legionella-DNA detection methods such as the qPCR described by Mentasi et al.18 and Benitez and 
Winchell19 avoids the shortcomings of urinary antigen detection and allows identification of the DNA of all the 
serogroups of L. pneumophila and all the species of Legionella. Furthermore, DNA detection methods are rapid 
and offer high sensitivity and low cross-reactivity3,6,20.
At present, DNA detection is the only method able to diagnose LD due to L. pneumophila non-sg 1 and Legionella 
non-pneumophila within a short time, while the patient is still in hospital and can be adequately treated accord-
ing to the accurate diagnosis. The sensitivity and specificity of the diagnosis of LD can be increased by combining 
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antigen Culture ST flaA pilE asd mip mompS proA neuA
1 Sporadic case (03.2017) + − 1177 1 4 3 1 2 1 1
2 Sporadic case (02.2017) + − 2 4 18 1 − 1 3
3 Sporadic case (12.2016) + − NA1 4 10 15 3 21 14 9
4 Outbreak 1 + − 3 10 − 10 11 − 6
5 Outbreak 1 + − 62 8 10 3 15 18 1 6
6 Sporadic case (12.2016) + − NA2 6 4 15 28 9 14 9
7 Sporadic case (12.2016) + − − 10 15 1 9 4 11
8 Outbreak 2 + − 92 2 3 18 5 5 1 2
9 Outbreak 2 + − 62 8 10 3 15 18 1 6
10 Outbreak 3 + − 92 2 3 18 5 5 1 2
11 Outbreak 3 + − NA3 4 7 11 3 11 14 9
12 Outbreak 3 + + 146 2 10 18 10 2 1 6
13 Sporadic case (10.2016) + − − − − − − − −
14 Outbreak 4 + − 42 4 7 11 3 11 12 9
15 Outbreak 4 + − − − − 1 11 − −
16 Sporadic case (09.2016) + − 37 3 4 1 1 14 9 11
17 Sporadic case (09.2016) + − NA4 3 10 14 28 9 14 9
18 Sporadic case (09.2016) + − NA5 2 3 6 10 2 5 9
19 Sporadic case (09.2016) + − − 4 3 1 11 5 1
20 Sporadic case (09.2016) + − 4 7 − 3 − 12 9
21 Outbreak 5 + − − 10 − 10 11 3 20
22 Outbreak 5 + − − 4 1 − − 9 11
23 Sporadic case (04.2016) + − − − − − − − −
24 Sporadic case (04.2016) + − − − − − − − −
25 Sporadic case (02.2016) + − 9 3 10 1 3 14 9 11
26 Outbreak 6 + − 146 2 10 18 10 2 1 6
27 Outbreak 6 + − 146 2 10 18 10 2 1 6
28 Sporadic case (01.2016) + − − − − − − − −
29 Sporadic case (12.2015) + − 448 2 3 18 10 2 1 6
30 Sporadic case + − 4 10 3 28 9 4 −
31 Sporadic case + − 2 − 1 13 9 1 6
32 Sporadic case (10.2015) + − 17 2 10 3 28 9 4 6
33 Sporadic case (10.2015) + + 20 2 3 18 15 2 1 6
34 Sporadic case (10.2015) + − NA6 2 10 3 28 9 4 2
35 Sporadic case (10.2015) + − NA7 2 3 18 28 5 4 2
36 Sporadic case (10.2015) + − 17 2 10 3 28 9 4 6
37 Sporadic case (10.2015) + − 2 10 3 28 9 − 9
38 Sporadic case (10.2015) + − 1581 6 10 2 28 9 14 9
39 Sporadic case (10.2015) + − 3 4 1 1 − 9 11
40 Outbreak 7 + − 2 10 3 28 9 − 6
41 Outbreak 7 + − 444 2 10 22 10 2 1 6
42 Outbreak 7 + − 2 − − 10 2 1 6
43 Outbreak 8 + − 92 2 3 18 5 5 1 2
44 Outbreak 8 + − 92 2 3 18 5 5 1 2
45 Sporadic case (09.2015) + − 62 8 10 3 15 18 1 6
46 Sporadic case (09.2015) + − 1581 6 10 2 28 9 14 9
47 Sporadic case (09.2015) + − 2 10 3 5 9 1 −
48 Sporadic case (09.2015) + − 372 2 10 3 28 9 4 1
49 Sporadic case (08.2015) + − NA6 2 10 3 28 9 4 2
50 Sporadic case (07.2015) + − 2 4 3 28 − 3 11
51 Sporadic case (07.2015) + − NA8 2 4 3 28 9 1 11
52 Sporadic case (07.2015) + − NA9 3 9 2 5 3 41 15
53 Sporadic case (05.2015) + − − − − − − − −
54 Sporadic case (01.2015) + − 2 3 3 28 − 1 6
55 Sporadic case (01.2015) + − 17 2 10 3 28 9 4 6
56 Sporadic case (01.2015) + − NA10 12 9 26 5 26 4 15
Continued
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“classical” and DNA-detection methods, particularly in cases with a low bacterial load and those caused by Legionella 
non-pneumophila sg 1, thus allowing identification of cases previously not detected by urinary antigen detection and 
culture3. The cases detected by DNA-method and/or urine antigen can be typed by Nested-SBT, without requiring 
the isolation of the bacterium. Although Nested-SBT takes from two to five days to obtain the results, its use con-
firms the diagnosis of LD and also obtains molecular-epidemiological data which can aid epidemiologic studies and 
shorten the period of six to 10 days needed to isolate the strain and apply the molecular method. Time is decisive in 
identifying the source of infection and avoiding cases that may result in large-scale outbreaks of LD.
In our study, Nested-SBT failed to detect specific Legionella DNA in only 8.1% of LD samples; these failures 
may have been due to poor sputum quality, or to the administration of antibiotic treatment a few days before 
sample collection, thus decreasing bacterial load and inhibiting detection. Furthermore, since all the samples 
were from patients with positive urine antigen, our results show that despite having an incomplete SBT profile, 
the amplification and sequencing of two genes was sufficient to confirm the diagnosis of cases clinically suspected 
of LD and to initiate appropriate treatment against Legionella.
Assessing the combination of real-time PCR and Nested-SBT to diagnose LD, Qin et al.21 described a similar 
efficiency to that recorded in our study. However, they only included samples which were positive with Real-Time 
PCR; they excluded pneumonia caused by Haemophilus and Streptococcus and did not assess the specificity of 
Nested-SBT in order to confirm its utility as a diagnostic tool versus other bacterial pneumonia.
One limitation of Nested-SBT is that the neuA gene found in some L. pneumophila isolates22 requires the ampli-
fication of the homologous neuA (neuAH) gene for their characterisation, and the Nested-SBT protocol is not 
designed to cover the neuAH gene. Therefore, cases requiring the neuAH gene amplification protocol for sequence 
typing would only achieve the ST profile of a maximum of six genes, and would always lack the neuA gene.
In the present study we confirmed the utility of Nested-SBT for performing molecular epidemiological studies 
in culture-negative samples. With this methodology we were able to amplify and sequence almost all the cases, 
while direct culture allowed epidemiological studies in only two. Furthermore, this typing tool reduces the time 
of typing result from 10–15 days to three to five days, since there is no need to wait for the isolation and growth 
of the bacteria.
To demonstrate further its utility and power in combination with DNA detection methods (qPCR) for avoid-
ing the culture stage, Nested-SBT should be applied in cases of pneumonia with suspicion of LD in which urinary 
antigen detection and direct culture are negative, and its specificity should be validated by applying the method 
to other pneumonias of different aetiological origin.
Material and Methods
Sample selection. A total of 62 respiratory samples from patients with Legionella clinically confirmed 
by positive urinary antigen tests from November 2014 to May 2017 were provided by the Epidemiological 
Surveillance Network of the Catalan Public Health Agency.
The study was conducted in accordance with the Declaration of Helsinki and Spanish law concerning clinical 
research. The protocols were approved by the local Human Research Ethical Committee at the Germans Trias i 
Pujol Hospital (Badalona). Since 2001, our laboratory has been the reference laboratory for Legionella typing in 
LD outbreak/cluster investigations in Catalonia. Since the clinical isolates studied were anonymised and referred 
to our laboratory for molecular typing by the health authorities in accordance with Spanish legislation, the need 
for informed consent was waived by the local Human Research Ethical Committee.
Microbiological culture. The respiratory samples were cultured on buffered charcoal yeast extract (BCYE) 
agar and glycine vancomycin polymyxin cycloheximide (GVPC) agar or BCYE supplemented with cefamandole, 
polymyxin B and anisomycin (BMPA) on microbiological agar plates according to the routine microbiological 
standards in each hospital.
L. pneumophila identification and monoclonal antibody (MAb) subtyping. L. pneumophila iso-
lates were identified by the Monofluo IFA test kit (Genetic Systems Corp., Redmond, WA, USA) and were dif-
ferentiated as serogroup 1 or non-serogroup 1 by immunoagglutination serotyping (Oxoid Legionella Latex; 
Germany). The isolates were stored in glycerol-brain heart infusion (BHI) (Oxoid) at −80 °C.
Monoclonal antibodies (MAbs) from the Dresden Panel were used to determine the serogroup of L. pneu-




antigen Culture ST flaA pilE asd mip mompS proA neuA
57 Sporadic case (11.2014) + − 372 2 10 3 28 9 4 1
58 Sporadic case (11.2014) + − 2 7 − 28 9 4 9
59 Sporadic case (11.2014) + − NA11 2 7 3 28 9 4 9
60 Sporadic case (05.2017) + − 1 1 4 3 1 1 1 1
61 Sporadic case (05.2017) + − − 4 − 1 − − −
62 Sporadic case (05.2017) + − 146 2 10 18 10 2 1 6
Table 1. Clinical cases included in the study. Urinary antigen and culture results are marked as (+) (positive) 
or (−) (negative) results. An (−) in the allelic profile indicates a failed gene. NA: no ST assigned in the ESGLI 
database.*Epidemiological relationship between cases before the molecular results; in sporadic cases the month 
and year of the sample are included in brackets.
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the reaction against a specific antibody by indirect immunofluorescence for each serogroup. The phenotypic 
subgroup of L. pneumophila sg 1 was based on the reaction against seven MAbs using an indirect immunofluores-
cence assay, dividing sg 1 into nine different phenotypic subgroups according to a flow chart23.
SBT (DNA amplification from isolates). Genomic DNA was extracted from isolates obtained from res-
piratory samples using the Chelex™ extraction technique (Bio-Rad Laboratories, CA, USA). The seven target 
genes (flaA, pilE, asd, mip, mompS, proA and neuA) were amplified using the primers and amplification protocol 
provided by the ESGLI (V.5)14.
Nested-SBT (DNA amplification from respiratory samples). The DNA of the respiratory samples was 
extracted using the Dneasy Blood&Tissue Kit (Qiagen, Germany) following the manufacturer’s instructions. The 
seven target genes (flaA, pilE, asd, mip, mompS, proA and neuA) were amplified using two amplification rounds 
with the primers and amplification protocol provided by the ESGLI14.
We included no template controls (NTC) for each pair of primers in the first and second amplification steps. 
Furthermore, during the second round of PCR we amplified the NTC of the first round of the nested-PCR. If 
any NTC was positive, all PCR reactions in that set were considered to be contaminated and were discarded and 
repeated.
DNA sequencing and allele assignment. DNA sequencing was performed in a 3130xl (3100) ABIPrism 
genetic analyser (Applied Biosystems, Foster City, CA) at the Genomics Unit of the Health Science Research 
Institute Germans Trias i Pujol Foundation. Sequences were analysed using Sequence Scanner software v1.0 
(Applied Biosystems). Then, the allele number was assigned using the SBT-ESGLI Quality tool, and the ST pro-
files were defined with the SBT-ESGLI database.
Statistical analysis. Descriptive statistics were presented as frequencies with the prevalence (95% con-
fidence interval [CI]) for categorical variables. Concordance between culture and Nested-SBT as a molecular 
epidemiological tool was analysed using Cohen’s kappa (k) test (95% CI). To compare the performance of the 
diagnostic tests, we applied the McNemar exact statistical test with continuity correction for correlated propor-
tions (p < 0.05).
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